Abstract: PinX1 plays positive and negative roles in the maintenance of telomerase and telomeres, as well as in tumorigenesis. The aim of the present study was to investigate the expression and clinical significance of PinX1 in colorectal carcinoma (CRC) and to determine the effect of PinX1 on CRC cell proliferation and apoptosis. A total of 86 CRC patients treated with radical resection and 5-fluorouracil-based adjuvant chemotherapy were enrolled in this study. The expression dynamics of PinX1 was detected by immunohistochemistry in the CRC patients and 25 normal colonic mucosa controls. PinX1 expression was significantly reduced in tumor tissues as compared to normal tissues, and the rate of PinX1 protein low/negative expression in CRC and normal tissues was 60% (52/86) and 24% (6/25), respectively (P=0.037). In addition, PinX1 downregulation was significantly associated with short overall survival (P=0.016) and disease-free survival (P=0.042) in CRC patients. Cox proportional hazards model further revealed that PinX1 expression was an independent factor in predicting overall survival and disease-free survival for CRC patients. Furthermore, we demonstrated that ectopic overexpression of PinX1 in CRC cells inhibited their proliferation, promoted apoptosis, repressed telomerase activity, and induced telomere shortening. These findings suggest that PinX1 may be a prognostic biomarker for CRC patients' survival and that it inhibits cell proliferation and promotes apoptosis by repressing telomerase activity and inducing telomere shortening. Targeting PinX1 may therefore provide a novel therapeutic strategy for CRC patients.
Introduction
Colorectal carcinoma (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide. 1, 2 The incidence of CRC has increased annually, together with lifestyle changes, and is ranked the fifth most commonly diagnosed cancer in the People's Republic of China. 3 CRC arises through a multistep carcinogenic process during which cells acquire the hallmarks of cancer, such as immortality. 4, 5 This involves the stabilization of telomere length, which is achieved by telomerase activation in over 85% of human tumors. [6] [7] [8] Telomerase is a specialized ribonucleoprotein reverse transcriptase required for the de novo synthesis of telomeric DNA at chromosomal ends after the cell cycle. It is repressed in the majority of somatic cells, but is reactivated in most human cancer types, and these malignant cells maintain their telomere lengths and demonstrate unlimited proliferative 
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Qian et al capacity. 9, 10 Thus, the maintenance of telomeres by telomerase constitutes part of CRC tumorigenesis and could be a promising target for predicting clinical prognosis and cancer therapy.
The nuclear protein Pin2-TRF1 interacting protein (PinX1) was originally shown to be a telomerase/telomere interacting factor, which is evolutionary conserved from yeasts to humans. Zhou and Lu 11 found that PinX1 bound the telomerase catalytic protein subunit telomerase reverse transcriptase, and the PinX1-telomerase reverse transcriptase interaction has been experimentally shown to have a telomere activity-inhibitory effect, suggesting it is an intrinsic telomerase inhibitor and a putative tumor suppressor. Other groups demonstrated that PinX1 −/− mice are embryonic lethal, while PinX1
+/− mice spontaneously develop malignant tumors resulting from chromosomal instability. 12 Our most recent in vitro and in vivo studies revealed that the ectopic overexpression of PinX1 in telomerase-positive cancer cells resulted in resistance to DNA damaging agents and ionizing radiation, which could be attributed to the maintenance of telomere stability, and the reduction of DNA damage-induced cell apoptosis and mitosis catastrophe. [13] [14] [15] Furthermore, the high expression of PinX1 positively correlated with esophageal squamous cell carcinoma patient resistance to chemoradiotherapy and was a strong predictor for short disease-specific survival in esophageal squamous cell carcinoma patients. 15 However, Deng et al reported that PinX1 expression was decreased in CRC and that its downregulation was significantly associated with poorer 5-year overall survival (OS) and disease-free survival (DFS) rates. 16 These contradictory results suggested that PinX1 abnormalities may be tumor type-specific and could play different roles in cancer progression at different stages.
In this study, we investigated PinX1 regulation in CRC patients and examined its effect on CRC cell apoptosis, proliferation, and telomere maintenance. Our findings highlight the functions and roles of PinX1 in CRC and suggest PinX1 may be used as a novel prognostic marker and potential therapeutic target for CRC patients. immunohistochemistry Immunohistochemistry (IHC) staining was performed on 5 μm tissue sections rehydrated through graded alcohols. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15 minutes. An antigen retrieval process was accomplished in a microwave oven with 10 mM citrate buffer, pH 6.0, for 15 minutes. Nonspecific binding was blocked with 10% normal rabbit serum for 10 minutes. The tissue slides were incubated with the rabbit polyclonal antibody against human full-length PinX1 (ProteinTech Group, Inc., Rosemont, IL, USA; 1:100 dilution) overnight at 4°C. Subsequently, the slides were sequentially incubated with biotinylated goat antirabbit immunoglobulin (ZSGB-BIO, Beijing, People's Republic of China) at a concentration of 1:100 for 30 minutes at 37°C and then reacted with a streptavidin-peroxidase conjugate for 30 minutes at 37°C and 3′-3′ diaminobenzidine as a chromogen substrate. The nucleus was counterstained using Meyer's hematoxylin. Known immunostaining-positive/negative slides were used as positive and negative controls. Two independent observers blinded to the clinicopathologic information performed scoring using a previously validated scoring system for PinX1 expression. 17 This system scores nuclear PinX1 expression by recording the percentage of nuclei staining positive for OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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roles of PinX1 in colorectal carcinoma the PinX1 protein, irrespective of staining intensity, in which PinX1 immunoreactivity was classified into two groups: low expression, when PinX1-positive cells were ,50%, including samples with negative expression of PinX1 ( Figure 1B and C), and high expression, when at least 50% of the cells showed positive immunoreactivity of PinX1 in the nuclei ( Figure 1A and D) . In an IHC study, a minimum of 500 epithelial cells was counted for each normal or tumor case.
Plasmid construction, lentivirus production, and transduction
The full-length PinX1 constructs were amplified and cloned into the pCDH-CMV-MSC-EF1-coGFP cDNA expression lentivector (System Biosciences, Palo Alto, CA, USA). Then, the lentiviral expression construct and packaging plasmid mix were cotransfected into 293 cells to generate recombinant lentivirus according to the manufacturer's manual. SW1116 
Western blotting assay
Cells were lysed in lysis buffer. BCA kit (Pierce, Rockford, IL, USA) was used to determine protein concentrations. SDS-PAGE and Western blotting were done according to standard procedures. Proteins were detected with antibodies recognizing full-length PinX1 (45 kDa). GAPDH (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used as a loading control.
MTT proliferation assay
Cell viability was measured with the use of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) proliferation assay (Sigma-Aldrich Co.). Briefly, cells were seeded in 96-well plates and cultured. Cell viability was examined following standard procedures. Experiments were done in triplicate.
Annexin V-APC/propidium iodide flow cytometry apoptosis assay Annexin V-APC and propidium iodide stains were used to determine the percentage of cells undergoing apoptosis. The apoptosis assay was conducted using the protocol supplied by the manufacturer (BD Biosciences, San Jose, CA, USA). Each sample was then subjected to analyses by flow cytometry (BD FACSCanto II Flow Cytometer, BD Biosciences).
Telomerase activity assay
Telomerase activity was measured with the TRAPeze telomerase detection kit (Chemicon, Temecula, CA, USA). PCR products were separated by electrophoresis on a 12.5% nondenaturing polyacrylamide gel, visualized by SYBR green (Thermo Fisher Scientific) staining and semiquantitated according to the manufacturer's instruction. Briefly, telomerase activity consists of the intensity of the TRAP product band and the processivity of TRAP ladders.
Telomere lengths analysis
Two micrograms of genomic DNA from tissue extracts were doubly digested with Hinf I and Rsa I overnight at 37°C. The DNA products of enzymes digestion were electrophoresed on 0.8% agarose gel and transferred onto a nylon membrane for hybridization with digosin-labbed (TTAGGG)3 oligos. The hybridization signal was detected by the AP-conjugated antidigosin antibodies (Hoffman-La Roche Ltd., Basel, Switzerland) and imaged by CDP-Star (Hoffman-La Roche Ltd. 
Results
PinX1 was downregulated in crc tissues
We examined PinX1 protein expression using IHC in 86 cases of primary CRC and 25 normal colonic mucosa controls ( Figure 1A-D) . Low/negative PinX1 expression was observed in 60% (negative: 9; low: 43, 52/86) of CRC tissues and only 24% (negative: 0; low: 6, 6/25) of normal colonic mucosa. High PinX1 expression was observed in 40% (34/86) of CRC tissues but 76% (19/25) of normal colonic mucosa (P=0.012, Figure 1E ). The association between PinX1 expression and clinicopathological features of the 86 CRC cases is summarized in Table 1 . PinX1 expression correlated closely with tumor differentiation (P=0.037), but no significant association was found between PinX1 expression and other clinicopathological variables, such as patient age, WHO grade, tumor location, or tumor size (P.0.05).
low expression of PinX1 correlates with poor crc survival Univariate analysis found that low PinX1 expression was significantly correlated with poor OS (Figure 2A , P=0.016) and DFS ( Figure 2B , P=0.042) in CRC patients. Multivariate analysis showed that PinX1 expression as well as tumor node metastasis stage, local invasion, and lymph node metastasis were independent predictors of patient OS and DFS (P=0.015, 0.006, 0.031, and 0.014, respectively; Table 2 ).
PinX1 suppresses proliferation and promotes apoptosis in crc cells
To explore the potential cancer-suppressive role of PinX1 in CRC, the PinX1 construct was stably transfected into the SW1116 and SW480 cell lines. PinX1 expression was confirmed by Western blotting (Figure 3A) , and the MTT assay showed that ectopic overexpression of PinX1 inhibited cell growth compared with blank and vector-transfected control cells ( Figure 3B , **P,0.01). To determine whether PinX1 has a proapoptotic effect on CRC cells, the Annexin V/propidium iodide staining cell apoptosis assay was performed. Flow cytometry analysis then indicated that 
PinX1 suppresses telomerase activity and induces telomere shortening in crc cells
PinX1 functions as an intrinsic inhibitor of telomerase enzymatic activity. TRAP assays in our study consistently indicated that the ectopic overexpression of PinX1 significantly suppressed telomerase enzymatic activities in SW1116 cells (approximately fourfold, Figure 4A ). SW1116 cells overexpressing PinX1 were also shown to have reduced telomere lengths compared with control vector cells (approximately twofold, Figure 4B ). Together, these results demonstrate that PinX1 suppresses telomerase activities and induces telomere shortening in CRC cells. Notes: *Chi-square test; **mean age; ***mean tumor size. Data in bold indicates statistical significance (P,0.05). 
Discussion
Surgical resection and adjuvant chemotherapy are standard, effective treatments for CRC patients in the early stages or with locally advanced disease. 18, 19 However, CRC patients with the same clinical stage often display considerable variability in their response to these anticancer therapies because of differences in intrinsic molecular characteristics. 20 Therefore, there is an urgent need to identify subgroups of OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
Dovepress
4827
roles of PinX1 in colorectal carcinoma patients with different outcomes to develop individualized treatments. Although CRC has been widely studied, the identification of specific genetic alterations associated with patient outcomes remains limited. 21 Thus, further work is needed in the development of reliable molecular biomarkers, not only for CRC but also for an array of human neoplasms.
Telomerase has been implicated in human cancers for its role in counteracting the telomere shortening-induced replicative senescence. Targeting pathways involved in the maintenance of telomerase/telomeres may be therefore a useful anticancer therapeutic strategy. 22, 23 Originally, PinX1 was identified as an intrinsic telomerase inhibitor and a putative tumor suppressor through its binding to and inhibition of telomerase. 11 However, we previously demonstrated that PinX1 had a positive role in regulating telomere maintenance by telomerase and that it inhibited the drug-induced apoptotic effect in telomerase-positive cancer cells, which may be caused by the PinX1-mediated telomerase/telomere recruitment pathway. 13, 15 More recently, Deng et al reported that PinX1 expression was significantly reduced in CRC tissues compared with normal tissues and that its downregulation was significantly associated with adverse 5-year OS and DFS in CRC patients treated with radical resection and 5-fluorouracil-based adjuvant chemotherapy. 16 However, our studies reported high PinX1 expression in ~60% of esophageal squamous cell carcinoma patient (n=157) tissues from two cancer centers, but high PinX1 expression in only 16.7% of normal esophageal mucosa specimens. Further correlation analysis showed that high PinX1 expression was positively correlated with poor disease-specific survival in esophageal squamous cell carcinoma patients treated with chemoradiotherapy.
14 These contradictory results led us to detect PinX1 expression in CRC tissues from our own hospital.
In accordance with Deng et al's reports, we found that the expression of PinX1 in CRC tissues was lower than in normal noncancerous tissues. 16 Moreover, low PinX1 expression was an independent predictor for short OS and DFS in CRC patients treated with radical resection and 5-fluorouracil-based adjuvant chemotherapy. We believe that telomerase/telomere pathways play critical roles in cell differentiation and tumorigenesis. 24 As shown in Table 1 , we found that low expression of PinX1 was closely correlated with poor differentiation of CRC, indicating that PinX1 may play roles in tumor progression through regulating telomerase/telomere pathways. In addition, we observed that ectopic overexpression of PinX1 could increase the sensitivity of CRC cells to 5-fluorouracil, the main component of the adjuvant chemotherapy regimen administered to our patients with CRC ( Figure S1 ), which further supports our clinical data and those of Deng et al. 16 Our results, together with those of others, suggest that PinX1 plays a dual role in cancer progression and that the abnormalities and/or functions of PinX1 in tumorigenesis are complicated and possibly tumor type-specific. 
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Qian et al Cell proliferation and apoptosis are important stages of cancer development and therapy and are regulated by multiple molecular pathways, including telomere maintenance. [25] [26] [27] Our current in vitro results showed that the ectopic restoration of PinX1 suppressed cell proliferation and promoted cellular apoptosis in both SW1116 and SW480 cells. Our previous study demonstrated that upregulation of PinX1 in urothelial carcinoma of the bladder cells increased the proportion of cells in the G0/G1 phase and decreased those in the S phase through the p16/cyclin D1 pathway. 28 We obtained similar results for SW1116 cells in the present study ( Figure S2 ). These results suggest that PinX1 may have a tumor suppressive function in CRC progression.
Based on our recent work and other previous studies, we propose that PinX1 regulates the telomere maintenance of cancer cells through at least two distinct mechanisms. In the first, we postulate that PinX1 induces telomere dysfunction by binding to telomerase and directly suppressing its activity. In the second, we speculate that PinX1 plays a positive role in telomere length regulation through stimulating the access of telomerase to telomeres.
Zhang et al 29 previously revealed that PinX1 without the G-patch motif (69-328 amino acid) induced cell apoptosis and G1 arrest, but had no effects on telomerase activity in CRC SW480 cells. However, the detailed role of PinX1 in telomerase/telomere regulation has not been clearly elucidated in CRC cells. Herein, we hypothesized whether the reintroduction of full-length PinX1 would regulate telomerase activity and telomere length in CRC cells. Our results clearly showed that telomerase activity is markedly inhibited when the telomere length is dramatically shortened in full-length PinX1-restored SW1116 and SW480 cells. G-patch motif of PinX1 may play critical roles in regulating telomerase activity in CRC cells. Moreover, in our IHC study, a significant inverse correlation of PinX1 expression and hTERT expression was found in our CRC patients ( Figure S3 ). This result was in accordance with previous reports 16, 17 and provides evidence of a telomerase-inhibited function of PinX1 in CRC.
To our knowledge, the maintenance of telomere stability by telomerase is required for the immortalization and rapid growth of almost all cancer cells. 30 Moreover, telomere dysfunction-induced senescence and/or apoptosis are important mechanisms of tumorigenesis inhibition in humans while the disruption of telomere maintenance can enhance cancer cell sensitivity to chemotherapeutic agents and ionizing radiation. 31, 32 Therefore, our findings strongly suggest that the functional loss of PinX1 leads to enhanced telomerase activity and telomere stabilization. In turn, this promotes cellular proliferation and cellular resistance to apoptosis, which consequently favors CRC progression. Thus, the examination of PinX1 may be used as an effective tool to predict the outcome of CRC patients and optimize the making of clinical decisions.
Conclusion
In summary, we describe the expression pattern of PinX1 in human CRC. Our results provide a basis for the concept that low PinX1 expression, as revealed by IHC, may be a novel predictor of aggressive CRC and an independent prognostic factor for CRC patients. Furthermore, functional and mechanistic studies suggest that PinX1 inhibits cell proliferation and promotes apoptosis via the suppression of telomerase activity and the shortening of telomere length in CRC cells. Thus, targeting of the PinX1-mediated telomerase/telomere maintenance pathway might represent a novel therapeutic strategy to improve the outcome for CRC patients. 
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